clinical trial · NCT02057380
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Global Development, Inc.·phase2·completed·n = 13
Advanced Solid TumorslinsitiniberlotinibpaclitaxelBortezomibDexamethasone
brief summary
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
started
Apr 16, 2014
primary completion
Oct 14, 2016
completion
Dec 21, 2016
last updated
Nov 20, 2024
official title
A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol